At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 172 enrolled
Drug / intervention
A-101 Vehicle +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Vehicle Controlled, Parallel Group Study of the Dose-Response Profile of A-101 Topical Solution in Subjects With Seborrheic Keratosis.
In Brief
A Phase 2 clinical trial evaluating A-101 Vehicle, A-101 (40) Topical Solution, and 1 other intervention for Seborrheic Keratosis. Completed, enrolled 172 participants across 5 sites.
Detailed Summary
The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101 solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeborrheic Keratosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
First PostedJun 2014
Primary CompletionDec 2014
TodayJul 2026
First PostedJun 11, 2014
Enrollment StartJun 1, 2014
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.1 years ago
Interventions
A-101 Vehicledrug
Placebo control
A-101 (40) Topical Solutiondrug
A-101 (40) Topical Solution - high dose
A-101 (32.5) Topical Solutiondrug
A-101 (32.5) Topical Solution - low dose